What diagnosis is indicated by a positive dexamethasone suppression test with a normal ACTH level, and what are the appropriate next steps?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 11, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Positive Dexamethasone Suppression Test with Normal ACTH: Diagnosis and Management

A positive dexamethasone suppression test (failure to suppress cortisol) combined with normal ACTH levels most strongly suggests ACTH-independent Cushing's syndrome from an adrenal source, typically an adrenal adenoma or adrenocortical carcinoma. 1

Understanding the Biochemical Pattern

The combination of autonomous cortisol secretion (positive DST) with normal—rather than suppressed—ACTH creates a diagnostic challenge:

  • Classic ACTH-independent disease (adrenal adenoma or carcinoma) typically presents with low or undetectable ACTH (<5 ng/L or <1.1 pmol/L) because autonomous cortisol production suppresses pituitary ACTH secretion 2
  • Normal ACTH levels in the setting of failed cortisol suppression suggest either:
    • Early or mild adrenal disease where ACTH has not yet been fully suppressed 1
    • Pseudo-Cushing's state (physiologic hypercortisolism from obesity, depression, alcoholism, or uncontrolled diabetes) 1, 2
    • Technical issues with the DST (inadequate dexamethasone absorption, drug interactions) 3, 4

Immediate Next Steps

1. Confirm True Hypercortisolism

Repeat 1-2 additional first-line screening tests to exclude false-positive results and confirm genuine cortisol excess 3, 2:

  • Late-night salivary cortisol (LNSC): Collect 2-3 samples on consecutive evenings at usual bedtime; contraindicated in shift workers 2
  • 24-hour urinary free cortisol (UFC): Obtain 2-3 separate collections to account for day-to-day variability 2
  • Measure dexamethasone level from the original DST if serum was saved; levels <1.8 ng/mL indicate inadequate drug exposure and invalidate the test 3, 4

2. Exclude Pseudo-Cushing's States

Evaluate for conditions that activate the HPA axis without true neoplastic disease 1:

  • Psychiatric disorders (major depression, anxiety)
  • Alcohol use disorder
  • Severe obesity (BMI >35)
  • Uncontrolled diabetes mellitus
  • Polycystic ovary syndrome

If pseudo-Cushing's is suspected, treat the underlying condition and repeat biochemical testing after 3-6 months 3, 2. The Dex-CRH test or desmopressin test may help distinguish ACTH-dependent Cushing's from pseudo-Cushing's, though these are complex and should be performed by endocrinology 1.

3. Obtain Adrenal Imaging

If repeat testing confirms hypercortisolism, proceed immediately to adrenal CT or MRI 1:

  • CT is first-line for suspected adrenal pathology (less expensive, widely available) 1
  • Look for features suggesting malignancy: size >4 cm, irregular margins, inhomogeneous enhancement, Hounsfield units >10 on unenhanced CT 1
  • Adrenocortical carcinoma (ACC) must be considered, especially if the mass is large or has suspicious imaging features 1

4. Comprehensive Hormonal Evaluation for Adrenal Masses

Perform complete steroid profiling as recommended by ESMO guidelines for any adrenal mass with cortisol excess 1:

  • DHEA-S, 17-OH-progesterone, androstenedione, testosterone (serum)
  • 17-beta-estradiol (in men and postmenopausal women)
  • 24-hour urine steroid metabolite examination if available
  • Plasma and urine metanephrines to exclude pheochromocytoma (can be skipped if ACC is clearly established) 1

This "hormonal fingerprint" is critical for follow-up monitoring and helps differentiate benign adenomas from ACC, which often shows immature steroidogenesis patterns 1.

Critical Diagnostic Pitfalls

False-Positive DST Results

Common causes that must be excluded 3, 4:

  • CYP3A4 inducers: Phenobarbital, carbamazepine, phenytoin, rifampin, St. John's wort accelerate dexamethasone metabolism 3
  • Oral estrogen therapy: Increases cortisol-binding globulin, reducing free cortisol suppression 1, 3
  • Rapid gut transit or malabsorption: Inadequate dexamethasone absorption 3

When ACTH is "Normal" Rather Than Suppressed

This intermediate pattern warrants careful interpretation:

  • In early adrenal disease, ACTH may not yet be fully suppressed despite autonomous cortisol production 1
  • Cyclic Cushing's syndrome can produce variable ACTH levels; consider extended monitoring with multiple sequential LNSC measurements 1, 2
  • Bilateral adrenal macronodular hyperplasia occasionally shows partial ACTH suppression 5

When to Refer to Endocrinology

Immediate referral is indicated for 2:

  • Persistently abnormal screening tests (≥2 different modalities)
  • Any adrenal mass >4 cm or with suspicious imaging features
  • Discordant biochemical results (e.g., normal ACTH with failed DST suppression)
  • Clinical features strongly suggesting Cushing's syndrome (proximal myopathy, wide purple striae, easy bruising, facial plethora)

Algorithmic Approach Summary

  1. Verify the DST was performed correctly: Check for drug interactions, measure dexamethasone level if possible 3, 4
  2. Repeat screening: Obtain 2-3 LNSC and/or 24-hour UFC to confirm hypercortisolism 3, 2
  3. Exclude pseudo-Cushing's: Assess for obesity, depression, alcoholism, diabetes 1, 2
  4. If hypercortisolism confirmed: Obtain adrenal CT/MRI regardless of ACTH level 1
  5. Complete steroid profiling: DHEA-S, precursors, sex steroids, urine metabolites 1
  6. Surgical evaluation: If imaging shows adenoma or suspected ACC, refer to experienced adrenal surgeon 1

The key principle: normal ACTH does not exclude adrenal disease—imaging is mandatory when cortisol autonomy is confirmed, and adrenocortical carcinoma must always be considered in this clinical scenario. 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Diagnosing Cushing's Syndrome

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Dexamethasone Suppression Test Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Diagnosing Cushing's Syndrome with Dexamethasone Suppression Test

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.